Skip to main content

Table 3 Estimation of NS5A and NS5B properties by “protparam”

From: First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

PROTPARAM

NS5A 1a

NS5A 3a

NS5B 1a

NS5B 3a

Number of amino acids

229

233

591

591

Molecular weight

25,637.51

25,565.16

65,311.27

66,134.92

Theoretical pI

8.34

7.53

9.12

9.02

Estimated half-life

1.9 h (mammalian reticulocytes, in vitro)

1.9 h (mammalian reticulocytes, in vitro)

1.9 h (mammalian reticulocytes, in vitro)

1.9 h (mammalian reticulocytes, in vitro)

 > 20 h (yeast, in vivo)

 > 20 h (yeast, in vivo)

 > 20 h (yeast, in vivo)

 > 20 h (yeast, in vivo)

 > 10 h (Escherichia coli, in vivo)

 > 10 h (Escherichia coli, in vivo)

 > 10 h (Escherichia coli, in vivo)

 > 10 h (Escherichia coli, in vivo)

Instability index

Unstable

45.71

Unstable

44.48

Unstable

41.41

Unstable

45.66

Aliphatic index

70.66

69.53

86.7

85.37

GRAVY

 − 0.262

 − 0.226

 − 0.103

 − 0.219

  1. Almost both genotypes showed similar features. However, there were significant differences between pI of NS5S 1a and 3a genotypes